Bull markets do not run forever. Neither do they have a continuous run. Stock markets intermittently fall, sometimes correct and rarely turn into a bear market.
Although most investors tend to follow the “Buy low sell high” advice, but when Stock Market Corrections give an opportunity naïve panic and only suave investors make the most out of it.
Stock market falling is inevitable. A market correction always comes with a Potential buy opportunity. Falling share price lets you buy quality stocks at throwaway prices, with astute investors taking it like a big sale where falling stocks are available at discounted prices.
Three ASX stocks
Experience Co (ASX: EXP)
Experience Co underwent a remarkable financial transformation in FY23, marked by impressive performance indicators. The company reported a substantial increase in revenue, soaring to $108.6 million from $55.8 million in FY22, showcasing robust growth and market traction. Equally notable is the significant reduction in net loss, plummeting to $0.5 million from $13.6 million in the preceding fiscal year, indicating a decisive shift towards profitability and enhanced operational efficiency. Further, EXP achieved a noteworthy underlying EBITDA profit of $11.3 million, representing a substantial turnaround from a $2.4 million loss in FY22.
Moreover, the year-to-date FY24 revenue of $97.3 million marks a substantial 22% uptick compared to the previous corresponding period (PCP), highlighting the sustained momentum and robust performance of EXP.
Aeris Resources Limited (ASX: AIS)
Aeris Resources Limited and Helix, partners in the Canbelego project, have identified promising new drill targets. Recent geophysical surveys have revealed two potential parallel copper lodes near the existing Canbelego Main Lode Mineral Resource, suggesting an expansion of the deposit's scale. An Induced Polarisation (IP) survey has confirmed three distinct chargeability anomalies at a depth of 400 meters. To optimize their drilling strategy, they plan to conduct a Gradient Array IP survey along a 9km section of the Rochford Copper Trend.
Aeris Resources significantly bolstered liquidity, with usable cash and receivables reaching $44.7 million, alongside a closing cash balance of $22.7 million. This surge equips AIS with ample financial resources for operations and strategic initiatives. Moreover, Aeris invested $39 million in new mining projects, emphasizing AIS's commitment to growth.
Over the next six months, Aeris Resources is poised to focus on several pivotal initiatives across its mining projects. Efforts at Tritton Operations will prioritize enhancing production with the Avoca tank and Buderygar ramp-up.
Actinogen Medical Limited (ASX: ACW)
Actinogen Medical achieved approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its Innovation Passport application in the context of the Innovative Licensing and Access Pathway (ILAP) for Xanamem's potential use in treating Alzheimer's disease.
Actinogen is actively progressing with the XanaCIDD trial, anticipating results to be reported in the second quarter of 2024. This trial utilizes a primary endpoint for assessing cognition, validated through demonstrated benefits of Xanamem in two previous volunteer trials. The evaluation will not only focus on cognitive effects but will also measure the impact of Xanamem on depression.
A second significant clinical milestone on the horizon is the interim analysis of the XanaMIA Phase 2b trial, specifically involving patients with Alzheimer's disease. This interim analysis is expected to take place in the first half of the calendar year 2025. The company aims to achieve two major clinical readouts within the next 18 months, demonstrating its commitment to advancing research and understanding the potential benefits of Xanamem in both cognitive and depressive aspects of Alzheimer's disease.
No comments yet